BioWorld

Dec. 1, 2003

Praecis Gets First Approval: Plenaxis In Prostate Cancer

Prostate cancer patients gained a new treatment option on Nov. 25 as the FDA approved Plenaxis, a drug fully developed by Praecis Pharmaceuticals Inc. (BioWorld Today) Read More

Genentech's Avastin Misses Primary Endpoint In Phase II

Largest Stroke Trials Worldwide Compare Oral Anti-Ischemic Drugs With Current Warfarin Prevention

Medicare Bill To White House; Most Applaud New Regulations

Holiday Notice

Chronogen Series B Raises C$17M For Longevity Work

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Jan. 17, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for January 17, 2025

Caplyta star shines as J&J takes Intra-Cellular in $14.6B deal

BioWorld

The J.P. Morgan (JPM) Healthcare Conference in San Francisco kicked off with a resounding bang as Johnson & Johnson (J&J) disclosed plans to acquire...

Proteomics study explores how protein changes influence disease

BioWorld Science

Fourteen global pharma companies are getting together to conduct the largest proteomics study to date, analyzing 600,000 blood samples held in the UK Biobank to...

Illustration of cell receptors, antibodies

Abbvie and Simcere enter a $1B T-cell engager deal

BioWorld Asia

Abbvie Inc. and Simcere Zaiming Pharmaceutical Co. Ltd. are part of the volley of large deals accompanying the opening of the 43rd annual J.P. Morgan Healthcare...